"2011 has started in line with expectations if not better" commented CEO Marco Rubinstein. "With strong gross bookings and a strengthening pipeline of new opportunities, we believe we are on track for even better results in the second half of the year. Looking forward, we are encouraged by the increasing demand for our regulatory affairs services, as well as a robust pipeline of development proposals. We are focused on achieving our goals while carefully managing costs and building value for investors." In the second quarter, ELC GROUP is looking for a continued sequential increase in net revenues.
ELC GROUP is expected to turn its attention to acquisition targets in the specialty CROs and services companies’ landscape. Although ELC has traditionally focused its attention on opportunities based in Europe and Asia, the company is looking to make deals in other corners of the global marketplace as well.
ELC Group has also enhanced management team with key new members, including Dr. Paolo Biffignandi, Former TOPRA President as Advisory Board's Chairman.
Press contacts
Akhil Jain
ELC Group
ajain [at] elc-group [dot] com
Phone: +420 22 491 00 00
Miranda Rock
EvokedSet PR
Miranda [at] evokedset [dot] com
Phone: +44 (0)7957 391 498
About ELC Group
ELC GROUP is a leading global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries as well as REACH services to the Chemical industry .It helps companies that lack the resource (skills and knowledge) to cost effectively deliver regulatory affairs.
ELC Group provides full-service, multi-lingual consulting and cost-effective solutions to regulatory approvals using experts with in-depth knowledge and experience throughout the world. The team ranges from former FDA investigators to individuals with over 30 years of industry experience with broad capabilities. This includes integrated advanced technologies, regulatory affairs consulting and commercialisation services.
Please visit www.elc-group.com for further information
